文献速递甲状腺疾病

左甲状腺素治疗甲状腺自身免疫正常甲状腺孕妇妊娠结局的荟萃分析

A Meta-Analysis of Pregnancy Outcomes With Levothyroxine Treatment in Euthyroid Women With Thyroid Autoimmunity.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该荟萃分析纳入6项试验共2249例甲状腺自身免疫但甲状腺功能正常的孕妇,评估左甲状腺素对妊娠结局的影响。总体未观察到左甲状腺素改善妊娠结局,但个体化初始剂量与孕早期起始治疗分别与流产风险降低和早产率降低相关。

要点

  • 总体左甲状腺素补充未显著改善甲状腺自身免疫正常甲状腺孕妇的妊娠结局。
  • 个体化初始左甲状腺素剂量者流产风险降低(RR 0.62,95%CI 0.41-0.93)。
  • 孕早期起始左甲状腺素者早产率显著降低(RR 0.54,95%CI 0.31-0.92)。

核心结论

  • 无确切证据表明左甲状腺素补充可改善甲状腺自身免疫正常甲状腺孕妇的妊娠结局,但治疗策略尤其是剂量和起始时间可能重要。

研究设计与样本

  • 荟萃分析纳入6项随机对照试验和回顾性研究,共2249例甲状腺自身免疫但甲状腺功能正常的孕妇,检索截至2019年5月。

主要发现

  • 总体左甲状腺素补充对妊娠结局无有益影响。
  • 个体化初始左甲状腺素剂量者流产风险降低(RR 0.62,95%CI 0.41-0.93,I2=28%)。
  • 固定左甲状腺素剂量者流产风险无差异(RR 0.96,95%CI 0.74-1.24,I2=0%)。
  • 孕早期起始左甲状腺素者早产率显著低于未治疗或安慰剂组(RR 0.54,95%CI 0.31-0.92,I2=0%)。
  • 孕前起始治疗者早产率无改善(RR 1.14,95%CI 0.71-1.84,I2=0%)。

临床怎么用

  • 对甲状腺自身免疫但甲状腺功能正常的孕妇,可考虑个体化初始左甲状腺素剂量以降低流产风险。
  • 孕早期起始左甲状腺素治疗可能降低早产率,孕前起始治疗未见早产率改善。

局限性

  • 需要未来更多大型随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Thyroid autoimmunity (TAI), the most common cause of (sub)clinical hypothyroidism, is associated with adverse pregnancy outcomes. The benefits of levothyroxine (LT4) intervention in women with TAI remain controversial. OBJECTIVE: The purpose of this analysis is to determine the effect of LT4 on pregnancy outcomes in euthyroid women with TAI. DATA SOURCES: Databases were searched up to May 2019. STUDY SELECTION: Randomized controlled trails (RCTs) and retrospective studies that reported effects of LT4 administration on pregnancy outcomes in euthyroid women with TAI were screened. DATA EXTRACTION: Quality assessment and data extraction were conducted independently by 2 researchers. Conflicts were settled by a third researcher. DATA SYNTHESIS: Six trials comprising 2249 women were included. Overall, no beneficial effect on pregnancy outcomes was observed with LT4 supplementation. For women with individualized initial LT4 dosages, the risk of miscarriage decreased (relative risk [RR] 0.62, 95% CI: 0.41-0.93, I2 = 28%); there was no difference among women with fixed LT4 dosages (RR 0.96, 95% CI: 0.74-1.24, I2 = 0%). Women who initiated LT4 treatment in early pregnancy had a significantly lower preterm birth rate (RR 0.54, 95% CI: 0.31-0.92, I2 = 0%) than those who received no treatment or placebo. No improvement was observed among women who initiated treatment before conception (RR 1.14, 95% CI: 0.71-1.84, I2 = 0%). CONCLUSION: No definitive evidence showed improvement of pregnancy outcomes with LT4 supplementation in euthyroid women with TAI. However, therapeutic strategies, especially dosages and initial times of intervention, may be of great importance. Additional large RCTs are needed in the future.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sun X, Hou N, Wang H, et al. A Meta-Analysis of Pregnancy Outcomes With Levothyroxine Treatment in Euthyroid Women With Thyroid Autoimmunity. J Clin Endocrinol Metab. 2020. PMID: 31760420. doi:10.1210/clinem/dgz217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。